[A Clinical Observation of Concomitant Therapy of Erlotinib and Whole Brain Radiotherapy in Patients of NSCLC Combined with Brain Metastases.].

BACKGROUND Treatments to brain metastases in patients of NSCLC include operation, chemotherapy and radiotherapy, while the disease control rate of brain lesions is not so good, the media survival time is 4-6 months. Tyrosine kinase inhibitor erlotinib can get into blood-brain barrier as reported, and it is used as a effetive method to control brain metastases. The aim of this clinical observation was to evaluate the efficacy and adverse reactions after concomitant therapy of erlotinib and whole brain radiotherapy (WBRT) in patients of NSCLC with brain metastasis. METHODS This was a retrospective study. From 2006 to 2009, There were 12 cases of NSCLC with brain metastases. They were accepted the concomitant therapy of erlotinib and WBRT. The dose of erlotinib was 150 mg/d and the radiotherapy dose was (3 000-3 600) cGy/(10-12) F. After 2 months of radiotherapy the early efficacy was evaluabed. RESULTS The control rate of brain metastases was 91.7% with PR 66.7%, SD 25%. The major adverse reactions were skin rash (75%) and fatigue (91.7%). CONCLUSIONS The effect of the concomitant of erlotinib and WBRT in patients of NSCLC with brain metastases is better than WBRT alone, and the concomitant therapy is well tolerated.

[1]  Shenglin Ma,et al.  Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. , 2009, Lung cancer.

[2]  N. Viñolas,et al.  Feasibility and tolerability of the addition of erlotinib to 3D thoracic radiotherapy (RT) in patients (p) with unresectable NSCLC: A prospective randomized phase II study , 2008 .

[3]  Shenglin Ma,et al.  Concomitant treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib: P3-206 , 2008 .

[4]  J. von Pawel,et al.  Erlotinib in Patients with Previously Irradiated, Recurrent Brain Metastases from Non-Small Cell Lung Cancer: Two Case Reports , 2008, Oncology Research and Treatment.

[5]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[6]  M. Ladanyi,et al.  Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.

[7]  N. Willich,et al.  9 years tumor free survival after resection, intraoperative radiotherapy (IORT) and whole brain radiotherapy of a solitary brain metastasis of non-small cell lung cancer , 2006, Acta oncologica.

[8]  J. Minna,et al.  Clinicopathologic Significance of the Mutations of the Epidermal Growth Factor Receptor Gene in Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[9]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Y. Yatabe,et al.  EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma , 2005, The American journal of surgical pathology.

[11]  Leah E. Mechanic,et al.  Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[12]  S. Toyooka,et al.  The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  Takayuki Kosaka,et al.  Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.

[14]  K. Kiura,et al.  Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. , 2004, Lung cancer.

[15]  T. Miyazawa,et al.  Gefitinib as a first line of therapy in non-small cell lung cancer with brain metastases. , 2004, Internal medicine.

[16]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[17]  Maria Werner-Wasik,et al.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.

[18]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[19]  D. Rades,et al.  Treatment of Solitary Brain Metastasis , 2004, Strahlentherapie und Onkologie.

[20]  Allan H Friedman,et al.  Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  M. Kris,et al.  ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  E K Rowinsky,et al.  Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  E. Raaymakers,et al.  Brain metastases and non-small cell lung cancer. Prognostic factors and correlation with survival after irradiation. , 2001, Lung cancer.

[24]  E. Newlands,et al.  In vitro evaluation of temozolomide combined with X-irradiation , 1997, Anti-cancer drugs.

[25]  Wei Qi-chu.  The radiation-sensitizing effect of gefitinib on non-small cell lung cancer A549 cell line , 2007 .

[26]  Zhong Wen-zhao,et al.  Erlotinib in Lung Cancer - Molecular and Clinical Predictors of Outcome , 2006 .

[27]  N. Hanna,et al.  EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .

[28]  N. Viñolas,et al.  Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. , 2005, International journal of radiation oncology, biology, physics.

[29]  N. Saijo,et al.  Experimental and clinical effect of ACNU in Japan, with emphasis on small-cell carcinoma of the lung , 2004, Cancer Chemotherapy and Pharmacology.